MHRA Imposes Major Restrictions on Chikungunya Vaccine Following Safety Review
The Medicines and Healthcare products Regulatory Agency has announced significant new restrictions on a specific vaccine, strongly advising healthcare professionals not to administer it to patients aged 60 and over or individuals with four particular health conditions.
Global Safety Data Reveals Serious Adverse Reactions
The regulatory action concerns the Chikungunya vaccine IXCHIQ, which is now being restricted after global safety monitoring identified 28 cases of serious adverse reactions. Among these reported cases, three unfortunately resulted in fatal outcomes. The MHRA's decision follows a comprehensive review of emerging international safety data that raised concerns about specific patient populations.
The vaccine remains recommended for individuals between 18 and 59 years old who are at risk of Chikungunya infection and do not have the contraindicated health conditions. This represents a careful balancing of risks versus benefits for different demographic groups.
Detailed Restrictions and Affected Populations
The MHRA has specifically advised against using the IXCHIQ vaccine for the following groups:
- People aged 60 years and older
- Individuals with high blood pressure (hypertension)
- Those diagnosed with heart disease
- People living with diabetes
- Individuals suffering from chronic kidney disease
Additionally, the agency has recommended that people who are immunodeficient, immunosuppressed, or have a history of thymus disorders or thymectomy should avoid this vaccination. These restrictions were formally confirmed on February 11, 2026, following recommendations from the government's independent expert advisory committee on immunization.
Historical Context and Previous Precautions
The IXCHIQ Chikungunya vaccine initially received MHRA approval in February 2025. However, safety concerns emerged relatively quickly, leading the agency to implement a temporary precautionary pause on its use for people aged 65 and over in June 2025 while additional safety data was collected and analyzed.
The current restrictions represent a more comprehensive and permanent limitation based on the accumulated evidence from that ongoing safety review process.
Clinical Guidance for Healthcare Professionals
Healthcare professionals are now urged to conduct comprehensive risk assessments before considering the IXCHIQ vaccine for any patient. Particular caution is advised when evaluating individuals with two or more underlying chronic health conditions, even if those conditions aren't specifically listed among the primary restrictions.
The MHRA emphasizes that these precautions are necessary despite the vaccine's favorable profile for appropriate candidates—primarily healthy adults between 18 and 59 who face genuine risk of Chikungunya exposure.
Understanding Chikungunya Virus and Available Protection
Chikungunya is a viral infection transmitted through infected mosquitoes, first isolated during an outbreak in Tanzania in 1952. The name derives from the Makonde language phrase meaning 'that which bends up,' describing the characteristic crippling joint pain that often accompanies infection.
While some infected individuals experience no symptoms, others suffer severe reactions including sudden fever, intense pain in multiple joints, swelling, and rashes. Symptoms typically resolve within ten days, with most patients making full recovery according to official guidance.
There is currently no specific medication to prevent Chikungunya virus infection. For travelers to at-risk areas, vaccination represents the primary protective strategy. In the UK, two vaccines are approved for this purpose: IXCHIQ (now with these new restrictions) and Vimkunya.
The virus cannot spread through casual person-to-person contact like coughing or sneezing. It is primarily found in subtropical regions including parts of the Americas, Africa, Southeast Asia, India, and the Pacific Region. Accurate diagnosis can be challenging as symptoms may resemble other mosquito-borne illnesses like dengue fever.
